Activity

When trained with data augmentation by 3DGlow, the 3DDenseNet yielded a statistically significantly higher polyp classification performance than when it was trained with alternative augmentation methods.

The 3DGlow-generated synthetic polyps are visually indistinguishable from real colorectal polyps. Their application to data augmentation can substantially improve the performance of 3D CNNs in CADe for CT colonography. Thus, 3D Glow is a promising method for improving the performance of deep learning in CADe for CT colonography.

The 3D Glow-generated synthetic polyps are visually indistinguishable from real colorectal polyps. Selleck piperacillin Their application to data augmentation can substantially improve the performance of 3D CNNs in CADe for CT colonography. Thus, 3D Glow is a promising method for improving the performance of deep learning in CADe for CT colonography.

Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug-drug interactions (DDIs). The pharmacological burden may be further aggravated by the addition of treatments for COVID-19.

The aim of this study was to assess the risk of potential DDIs upon admission and during hospitalisation in patients with COVID-19 treated at our hospital.

We retrospectively analysed 502 patients with COVID-19 (mean age 61 ± 16 years, range 15-99) treated at our hospital with a proven diagnosis of SARS-CoV-2 infection hospitalised between 21 February and 30 April 2020 and treated with at least two drugs.

Overall, 68% of our patients with COVID-19 were exposed to at least one potential DDI, and 55% were exposed to at least one potentially severe DDI. The proportion of patients experiencing potentially severe DDIs increased from 22% upon of potentially severe DDIs. Given the high risk of cardiotoxicity and the scant and conflicting data concerning their efficacy in treating SARS-CoV-2 infection, the use of lopinavir/ritonavir and hydroxychloroquine in patients with COVID-19 with polypharmacy needs to be carefully considered.

To compare the technical efficacy and complications of the transarterial injection of a miriplatin-iodized oil suspension combined with radiofrequency ablation (RFA) or microwave ablation (MWA) in the treatment of small hepatocellular carcinomas (HCCs).

This retrospective study included 123 HCCs in 101 patients treated with the transarterial injection of a miriplatin-iodized oil suspension and RFA (MPT-RFA) (maximum diameter 1.5 [Formula see text] 0.5cm, range 0.6-3.0cm) and 68 HCCs in 49 patients treated with the transarterial injection of a miriplatin-iodized oil suspension and MWA (MPT-MWA) (maximum diameter 1.6 [Formula see text] 0.7cm, range 0.5-3.0cm). Technical success was defined as the achievement of an ablative margin of at least 5mm for each tumor. Technical success, complications, and local tumor progression were compared between the two groups.

The initial technical success rate was significantly higher with MPT-MWA (94.1%) than with MPT-RFA (76.4%; P = 0.003). The number of treatment sessions per nodule was significantly lower with MPT-MWA (1.1) than with MPT-RFA (1.3) (P = 0.004). The major complication rates were similar with MPT-RFA (5.8%) and MPT-MWA (2.7%) (P = 0.391). The one-year local tumor progression rate was similar between MPT-RFA (0%) and MPT-MWA (0%) (P = 0.73).

MPT-MWA may have improved therapeutic efficiency in the treatment of small HCCs.

MPT-MWA may have improved therapeutic efficiency in the treatment of small HCCs.

The treatment of breast ptosis using mastopexy associated with the inclusion of a silicone prosthesis in a single surgical procedure is a challenge for surgeons. The aim of this study is to describe the 15-year experience with the placement of silicone breast implants in double, subfascial and submuscular space, in the treatment of patients with breast ptosis, and to analyze the aesthetic results of patients who underwent such surgeries.

During the 15-year period, between 2005 and 2020, 640 mastopexies were performed with the inclusion of silicone breast implants in double space, with high-profile round polyurethane prostheses whose volumes ranged from 135 to 435ml, in patients with grade 2 and 3 breast ptosis.

The age of the patients ranged from 18 to 55years and the average age was 34years. The postoperative follow-up time was 18months. 400 patients (62.5%) had grade II ptosis, whereas 240 of them (37.5%) had grade III ptosis. The main complications were 19 cases (3%) of residual sagging skin, 19 case00266.

Despite a few studies evaluating the prognostic impact of coronary chronic total occlusion (CTO) in implantable cardioverter defibrillator (ICD) recipients, the impact of CTO on different types of recurrences of ventricular tachyarrhythmias, as well as their predictors has not yet been investigated in CTO patients.

A large retrospective registry was used including all consecutive patients with ventricular tachyarrhythmias undergoing coronary angiography at index from 2002 to 2016. Only ICD recipients with CTO were compared to patients without (non-CTO). Kaplan-Meier and Cox regression analyses were applied for the primary end point of first recurrence of ventricular tachyarrhythmias at 5years. Secondary end points comprised of the different types of recurrences, first appropriate ICD therapy and all-cause mortality at 5years.

From a total of 422 consecutive ICD recipients with ventricular tachyarrhythmias at index, at least one CTO was present in 25%. CTO was associated with the primary end point of first recurrence of ventricular tachyarrhythmias at 5 years (55% vs. 39%; log rank p = 0.001; HR = 1.665; 95% CI 1.221-2.271; p = 0.001), as well as increased risk of first appropriate ICD therapy (40% vs. 31%; log rank p = 0.039; HR = 1.454; 95% CI 1.016-2.079; p = 0.041) and all-cause mortality at 5years (26% vs. 16%; log rank p = 0.011; HR = 1.797; 95% CI 1.133-2.850; p = 0.013). Less developed collaterals (i.e., either ipsi- or contralateral compared to bilateral) and a J-CTO score ≥ 3 were strongest predictors of recurrences in CTO patients at 5years.

A coronary CTO even in the presence of less developed collaterals and more complex CTO category is associated with increasing risk of recurrent ventricular tachyarrhythmias at 5years in consecutive ICD recipients.

A coronary CTO even in the presence of less developed collaterals and more complex CTO category is associated with increasing risk of recurrent ventricular tachyarrhythmias at 5 years in consecutive ICD recipients.